Used in targeted cancer immunotherapy, particularly for tumors expressing CLDN6 (Claudin 6), such as certain testicular, ovarian, and endometrial cancers. It serves as a reference molecule in the development of anti-CLDN6 therapeutics, including antibody-drug conjugates (ADCs) and bispecific antibodies. Enables target validation, assay development, and pharmacokinetic studies during preclinical and clinical research. Supports evaluation of binding specificity, functional activity, and efficacy in tumor cell killing through immune effector mechanisms like ADCC (antibody-dependent cellular cytotoxicity). Also utilized as a benchmark in comparative studies of novel CLDN6-targeting biologics.